Switching Off Bacterial Resistance
Bioversys AG is a privately held Swiss biopharmaceutical company located at the Technology Park in Basel that focuses on research and development of small molecules which switch off drug resistance within bacterial pathogens and thereby restore the efficacy of approved antibiotics. Spun out of the ETH-Zurich in 2008, BioVersys has profound technological expertise that is based on solid IP. BioVersys has built up an innovative technology to screen and develop drugs that act more upstream than conventional antibiotics. BioVersys' compounds will be used in combination with an existing antbiotic, thereby renewing efficacy as well as intellectual property for the established drug.
Over the last three decades, the number of newly approved antibiotics has steadily declined. At the same time, resistance against existing drugs has become more and more prevalent. Antibiotic resistance, hence, is now recognized by the WHO as a major public health concern. BioVersys has a pipeline of promising compounds that address this concern. The company is currently at preclinical stage with proof-of-concept in animals already demonstrated.
For a short video about BioVersys, please click here (YouTube link, 2min54).
BioVersys is a dynamic, innovative and knowledge-driven startup company. We are constantly looking for talented and self-motivated people that would like to work in the multitasking environment of a start-up Company.